Eiger BioPharmaceuticals, Inc.
EIGRDelisted Apr 25, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001305253
Eiger BioPharmaceuticals, Inc. was delisted on Apr 25, 2024; its insiders filed their last Form 4 on Nov 2, 2023; 43 institutions reported holding it in 13F filings for Q4 2023, worth $4.16M in total; no superinvestor held it.
Holders of 5% or more of EIGR
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Eiger BioPharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Eiger BioPharmaceuticals, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
4 Schedule 13D and 13G filings on Eiger BioPharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 26, 2024 | Arkin Moshe | 13GOld format | – | – | – | SEC |
| Jul 1, 2024 | Arkin Moshe | 13D/AOld format | – | – | – | SEC |
| May 10, 20242:14 PM ET | Ameriprise Financial Inc | 13G/AOld format | – | – | – | SEC |
| Feb 14, 202410:55 AM ET | Ameriprise Financial Inc | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | 683 Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Dec 4, 2023 | Arkin Moshe | 13D/AOld format | – | – | – | SEC |
| Nov 24, 2023 | Arkin Moshe | 13DOld format | – | – | – | SEC |
| Nov 3, 2023 | Propel Bio Management, LLC | 13D/AOld format | – | – | – | SEC |
| Oct 20, 2023 | Propel Bio Management, LLC | 13DOld format | – | – | – | SEC |
| Sep 28, 2023 | Propel Bio Management, LLC | 13G/AOld format | – | – | – | SEC |
| Aug 15, 2023 | Propel Bio Management, LLC | 13GOld format | – | New | – | SEC |
| Jul 7, 20234:35 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Apr 18, 2023 | Arkin Moshe | 13G/AOld format | – | – | – | SEC |
| Apr 10, 20231:37 PM ET | Ameriprise Financial Inc | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2023 | 683 Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2023 | Adage Capital Partners GP, L.L.C. | 13G/AOld format | – | – | – | SEC |
| Feb 6, 20233:34 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 2, 2023 | Arkin Moshe | 13G/AOld format | – | – | – | SEC |
| Jan 10, 202312:12 PM ET | Ameriprise Financial Inc | 13G/AOld format | – | – | – | SEC |
| May 11, 20223:01 PM ET | Ameriprise Financial Inc | 13G/AOld format | – | – | – | SEC |
| May 2, 2022 | Adage Capital Partners GP, L.L.C. | 13GOld format | – | – | – | SEC |
| Mar 8, 2022 | Arkin Moshe | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | 683 Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Vivo Ventures VI, LLC | 13D/AOld format | – | – | – | SEC |
| Feb 2, 20227:11 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Jan 21, 20223:25 PM ET | Ameriprise Financial Inc | 13DOld format | – | – | – | SEC |
| Sep 10, 202110:31 AM ET | Ameriprise Financial Inc | 13G/AOld format | – | – | – | SEC |
| Aug 6, 2021 | Vivo Ventures VI, LLC | 13D/AOld format | – | – | – | SEC |
| Feb 16, 2021 | 683 Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Vivo Ventures VI, LLC | 13D/AOld format | – | – | – | SEC |
| Feb 11, 2021 | Adage Capital Partners GP, L.L.C. | 13G/AOld format | – | – | – | SEC |
| Jan 29, 20219:56 AM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Jan 11, 202111:46 AM ET | Ameriprise Financial Inc | 13GOld format | – | New | – | SEC |
| Jan 4, 2021 | Broadfin Capital, LLC | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Eiger BioPharmaceuticals, Inc. shares.
No Form 144 notices for Eiger BioPharmaceuticals, Inc. are on file.